Literature DB >> 28650451

Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation.

A Tichelli1, S Gerull1, A Holbro1, A Buser1, G Nair1, M Medinger1, D Heim1, J P Halter1, J R Passweg1.   

Abstract

Return to work is critical goal following HSCT. However, late effects may impede return to normal activity after HSCT. In the case of inability to work, patients may need a work disability pension to ensure a reasonable livelihood. This study evaluated inability to work and need for disability pension among long-term survivors and analyzed possible determinants of need for social support. This retrospective, single-center study included all HSCT patients surviving ⩾5 years seen at the outpatient clinic between January 2013 and August 2015. There were 203 patients, median age at HSCT 35 years, and 50 years at time of study; median time between HSCT and study control was 12 years; 178 had allo-HSCT, 187 had a malignant disease. At time of study, 156 (77%) were working full or part-time, 47 (23%) were not working. In total, 76 (37%) survivors were receiving a work disability pension compared to 3.17% of the Swiss working population. Patients with a disability pension were significantly older at HSCT, were more often living alone, had more active physical and mental late effects, and higher score of fatigue compared to patients without. These findings underline the importance of screening for employment and the social consequences of non-employment in long-term survivors after HSCT.

Entities:  

Mesh:

Year:  2017        PMID: 28650451     DOI: 10.1038/bmt.2017.115

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  24 in total

Review 1.  Assessing the impact of cancer on work outcomes: what are the research needs?

Authors:  John F Steiner; Tia A Cavender; Deborah S Main; Cathy J Bradley
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

2.  Occupational status among adult survivors following allo-SCT.

Authors:  J Winterling; E Johansson; A Wennman-Larsen; L-M Petersson; P Ljungman; K Alexanderson
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

3.  Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.

Authors:  C E Kiserud; U-M Fagerli; K B Smeland; Ø Fluge; H Bersvendsen; S Kvaløy; H Holte; A A Dahl
Journal:  Acta Oncol       Date:  2016-05       Impact factor: 4.089

4.  Mortality in relation to disability pension: findings from a 12-year prospective population-based cohort study in Sweden.

Authors:  Nadine E Karlsson; John M Carstensen; Sturla Gjesdal; Kristina A E Alexanderson
Journal:  Scand J Public Health       Date:  2007       Impact factor: 3.021

5.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

6.  Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation.

Authors:  Eleshia J Morrison; Shawna L Ehlers; Carrie A Bronars; Christi A Patten; Tabetha A Brockman; James R Cerhan; William J Hogan; Shahrukh K Hashmi; Dennis A Gastineau
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-21       Impact factor: 5.742

7.  Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.

Authors:  Monika Kirsch; Sandra A Mitchell; Fabienne Dobbels; Georg Stussi; Ethan Basch; Jorg P Halter; Sabina De Geest
Journal:  Eur J Oncol Nurs       Date:  2014-09-01       Impact factor: 2.398

8.  The prognosis for individuals on disability retirement. An 18-year mortality follow-up study of 6887 men and women sampled from the general population.

Authors:  Thorne Wallman; Hans Wedel; Saga Johansson; Annika Rosengren; Henry Eriksson; Lennart Welin; Kurt Svärdsudd
Journal:  BMC Public Health       Date:  2006-04-22       Impact factor: 3.295

9.  Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study.

Authors:  E M Denzen; V Thao; T Hahn; S J Lee; P L McCarthy; J D Rizzo; M Ammi; R Drexler; S Flesch; H James; N Omondi; E Murphy; K Pederson; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

10.  Why do those out of work because of sickness or disability have a high mortality risk? Evidence from a Scottish cohort.

Authors:  Frank Popham; Kathryn Skivington; Michaela Benzeval
Journal:  Eur J Public Health       Date:  2012-12-18       Impact factor: 3.367

View more
  10 in total

1.  Age and gender differences in financial distress among hematopoietic cell transplant survivors.

Authors:  Salene M W Jones; Jean C Yi; Heather S L Jim; Alison W Loren; Navneet S Majhail; Joseph Uberti; Victoria Whalen; Wendy M Leisenring; Mary E D Flowers; Stephanie J Lee; Karen L Syrjala
Journal:  Support Care Cancer       Date:  2020-01-08       Impact factor: 3.603

2.  High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.

Authors:  Koichi Miyamura; Takuya Yamashita; Yoshiko Atsuta; Tatsuo Ichinohe; Koji Kato; Naoyuki Uchida; Takahiro Fukuda; Kazuteru Ohashi; Hiroyasu Ogawa; Tetsuya Eto; Masami Inoue; Satoshi Takahashi; Takehiko Mori; Heiwa Kanamori; Hiromasa Yabe; Asahito Hama; Shinichiro Okamoto; Yoshihiro Inamoto
Journal:  Blood Adv       Date:  2019-02-12

Review 3.  Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation.

Authors:  Neel S Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-10-04       Impact factor: 4.213

Review 4.  Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients.

Authors:  Jennifer M Knight; Mallory R Taylor; Kelly E Rentscher; Elisabeth C Henley; Hannah A Uttley; Ashley M Nelson; Lucie M Turcotte; Natalie S McAndrew; Hermioni L Amonoo; Lathika Mohanraj; Debra Lynch Kelly; Erin S Costanzo
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR).

Authors:  Neel S Bhatt; Ruta Brazauskas; Heather R Tecca; Jeanette Carreras; Linda J Burns; Rachel Phelan; Rachel B Salit; Karen L Syrjala; Julie-An M Talano; Bronwen E Shaw
Journal:  Cancer       Date:  2018-10-12       Impact factor: 6.860

6.  Contribution of Sleep Disruption and Sedentary Behavior to Fatigue in Survivors of Allogeneic Hematopoietic Cell Transplant.

Authors:  Ashley M Nelson; Kelly A Hyland; Brent Small; Brittany Kennedy; Asmita Mishra; Aasha I Hoogland; Hailey W Bulls; Heather S L Jim; Paul B Jacobsen
Journal:  Ann Behav Med       Date:  2021-08-23

7.  Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.

Authors:  Neel S Bhatt; Ruta Brazauskas; Rachel B Salit; Karen Syrjala; Stephanie Bo-Subait; Heather Tecca; Sherif M Badawy; K Scott Baker; Amer Beitinjaneh; Nelli Bejanyan; Michael Byrne; Ajoy Dias; Nosha Farhadfar; César O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Robert J Hayashi; Sanghee Hong; Yoshihiro Inamoto; Kareem Jamani; Kimberly A Kasow; Nandita Khera; Maxwell M Krem; Hillard M Lazarus; Catherine J Lee; Stephanie Lee; Navneet S Majhail; Adriana K Malone; David I Marks; Lih-Wen Mau; Samantha J Mayo; Lori S Muffly; Sunita Nathan; Taiga Nishihori; Kristin M Page; Jaime Preussler; Hemalatha G Rangarajan; Seth J Rotz; Nina Salooja; Bipin N Savani; Raquel Schears; Tal Schechter-Finkelstein; Gary Schiller; Ami J Shah; Akshay Sharma; Trent Wang; Baldeep Wirk; Minoo Battiwalla; Hélène Schoemans; Betty Hamilton; David Buchbinder; Rachel Phelan; Bronwen Shaw
Journal:  Transplant Cell Ther       Date:  2021-04-22

8.  Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.

Authors:  Zheng-Yi Zhou; Wenxi Tang; Kathleen F Villa
Journal:  Clinicoecon Outcomes Res       Date:  2018-12-17

Review 9.  Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms.

Authors:  Rebecca A Harrison; Noha Sharafeldin; Jennie L Rexer; Brennan Streck; Melissa Petersen; Ashley M Henneghan; Shelli R Kesler
Journal:  Oncologist       Date:  2021-07-12

10.  Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors.

Authors:  Rahul Banerjee; Jean C Yi; Navneet S Majhail; Heather S L Jim; Joseph Uberti; Victoria Whalen; Alison W Loren; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-08       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.